Valence-Logo
Beliebt
Anmelden
Loading data for ACRV — first visit, this takes a few seconds.

Zur Watchlist hinzufügen

Acrivon Therapeutics Inc.

NasdaqGM: ACRV · Echtzeitkurs · USD
2.11
+0.06 (2.93%)
Zum Schluss: Aug 19, 2026, 5:23 PM

Acrivon Therapeutics Inc. (ACRV) Stock Price, Analysis & Data

2.93%

Keine Daten verfügbar

Geld1.14
Marktkapitalisierung90.42 Mio
Umsatz (TTM)n/a
Nettogewinn (TTM)-74.22 Mio
Beta1.86
EPS (ttm)-1.88
KGV (TTM)n/a
Forward-KGV-1.22
KBV (TTM)0.86
KUV (TTM)n/a
Earnings DateAug 14, 2025
Brief2.06
Volumen227,591
Ø Vol. (20D)414,504
Eröffnung2.06
Vortagesschluss2.05
Tagesspanne2.06 - 2.14
52-Wk Range1.27 - 3.56
Analystn/a
Kurszieln/a
Dividendenn/a
Ex-Dividenden-Datumn/a

Über ACRV

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are ...

[Mehr lesen]
Branche Biotechnology
Sektor Healthcare
IPO Datum Nov 15, 2022
Mitarbeiter 74
Börse NasdaqGM
Tickersymbol ACRV
Website https://acrivon.com
Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Acrivon Therapeutics 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -77.91 Mio, ein Rückgang von -3.29 %.

Finanzberichte

Gewinnüberraschung

Acrivon Therapeutics hat die Quartalszahlen am Aug 12, 2026 veröffentlicht:
  • Umsatz von $0 verfehlt die Erwartungen um $0, mit NaN% Wachstum im Jahresvergleich.
  • EPS von -0.43 übertrifft die Erwartungen um 0.07, mit 21.82% Wachstum im Jahresvergleich.

    • Nächste Ergebnisveröffentlichung

    Acrivon Therapeutics Inc. wird voraussichtlich die Quartalszahlen veröffentlichen am Aug 14, 2025, nach Börsenschluss.
    Analysten erwarten einen Umsatz von ... Upgrade
    news image

    vor 5 Monaten · Zacks

    Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why

    Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    news image

    vor 5 Monaten · MarketBeat

    Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer

    Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company’s ongoing ACR-368 registrational-intent Phase 2B study in endometrial cancer, with...

    news image

    vor 7 Monaten · Simply Wall St.

    Penny Stocks To Watch In January 2026

    As the U.S. markets grapple with recent declines and rising Treasury yields, investors are keenly observing potential opportunities in various sectors. Penny stocks, while often seen as relics of past...

    news image

    vor 7 Monaten · Simply Wall St.

    Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares

    Even if it's not a huge purchase, we think it was good to see that Peter Blume-Jensen, the Co-Founder of Acrivon...

    news image

    vor 7 Monaten · Zacks

    Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?

    Here is how Humacyte, Inc. (HUMA) and Acrivon Therapeutics, Inc. (ACRV) have performed compared to their sector so far this year.

    Seite 1 von 2